Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03502746Phase 2Terminated

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Role: lead

NCT04589832Phase 1Terminated

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Role: lead

NCT02348008Phase 1Completed

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Role: lead

All 3 trials loaded